Trial reportEuropean journal of drug metabolism and pharmacokinetics2025
A Multicenter, Randomized, Open-Label, Active-Controlled, Parallel-Group Study Evaluating the Pharmacokinetics of Single-Dose Tapentadol Hydrochloride Intravenous Infusion and Tapentadol Hydrochloride Oral Tablets in Patients with Pain.
Trial report in European journal of drug metabolism and pharmacokinetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesTapentadol is a novel, centrally acting, potent analgesic with a dual mechanism of action on µ-opioid receptors and noradrenaline reuptake in the central nervous system. This study was conducted to compare the pharmacokinetics, preliminary pharmacodynamics, and safety of single-dose tapentadol hydrochloride intravenous infusion (IV) with tapentadol hydrochloride oral immediate-release (IR) and tapentadol hydrochloride oral extended-release (ER).
methodsIn this randomized, open-label, multicenter, active-controlled, parallel-group phase 1 trial, 28 Chinese patients with moderate noncancer pain were randomly assigned in a 1:1:1 ratio to receive a single dose of either tapentadol IV (0.5 mg/kg), tapentadol IR (100 mg), or tapentadol ER (100 mg). Adverse events were monitored, serum samples were collected for pharmacokinetic analysis, and 11-point numeric rating scale (NRS) scores were recorded for preliminary pharmacodynamic evaluation during the study.
resultsThe geometric mean (geomean) absolute bioavailability of tapentadol IR and ER after a single-dose administration under fasting conditions was 44.3% (90% confidence interval [CI] 37.5-52.3) and 34.0% (90% CI 27.1-52.3), respectively. The NRS scores demonstrated a decreasing trend across all three groups. Treatment-related adverse event (TRAE) occurred in 50.0% (tapentadol IV), 70% (tapentadol IR), and 50.0% (tapentadol ER) of patients. No events led to dose adjustment or interruption or necessitated additional concomitant medication, and there were no serious adverse events (SAEs), withdrawals, or deaths.
conclusionsTapentadol IV exhibits precise pharmacokinetics, promising pharmacodynamic properties, and a favorable safety profile compared with IR and ER routes for patients with moderate noncancer pain, supporting further clinical research and development of tapentadol injection.
trial registrationhttp://www.chinadrugtrials.org.cn/ ; CTR20212327 2021-09-27.
Indexed as
Identifiers
41066048What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.